Prescriber is the leading UK journal for healthcare professionals focussing on prescribing and medicines management. The journal features articles on all areas of therapeutics and prescribing policy and is fully peer reviewed. The content is relevant and of interest to all prescribers and prescribing policy makers including GPs, pharmacists, nurses and hospital specialists. Access to all content is free to healthcare professionals following registration.Sign up for e-alerts and print copies

Latest News

Risk of intestinal obstruction with clozapine

In a Drug Safety Update, the Medicines and Healthcare products Regulatory Agency (MHRA) has warned of the potentially fatal risk of intestinal obstruction,...Read more

New NICE guideline on cystic fibrosis

NICE has published its first guideline on the diagnosis and management of cystic fibrosis (NG78). The guidance provides recommendations on monitoring the...Read more

Risk of serious liver damage with MS drug daclizumab

The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has recommended further restrictions to the use of the multiple sclerosis (MS) treatment...Read more

Pre-exposure prophylaxis for HIV prevention cost-effective

Introducing a pre-exposure prophylaxis (PrEP) programme for HIV prevention in the UK for men who have sex with men (MSM) is a cost-effective approach,...Read more

NICE publishes guidance on prescribing for acute sinusitis

NICE has published final guidance on antimicrobial prescribing for acute sinusitis (NG79). The guideline, developed in partnership with Public Health England,...Read more

Featured Articles

Treatment options for primary and secondary dysmenorrhoea
Dysmenorrhoea affects up to half of young women and can adversely affect quality of life, especially if severe. This article describes the distinguishing features of primary and secondary dysmenorrhoea and discusses the main treatment options for women presenting in primary care.
Click here to view

DPP-4/SGLT2 inhibitor combined therapy for type 2 diabetes
DPP-4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixed-dose combinations – Qtern and Glyxambi – have now been approved for the treatment of type 2 diabetes. This article discusses their clinical trial efficacy, adverse effects and place in therapy.
Click here to view

Communication in the age of digital healthcare
The surge of technology across healthcare is washing away labour-intensive practices and promises a cleaner, smarter future for GPs and prescribers. However, concern is growing that traditional lines of clinical communication could be drowned out by the race for progress across a troubled NHS.
Click here to view

Web design and marketing agency Leamington Spa